Made-in-India COVID-19 vaccine, Covaxin, neutralises multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well, the Indian Council of Medical Research (ICMR) said today.
Bharat Biotech's Covaxin has received Emergency Use Authorizations (EUAs) for COVID-19 treatment in India and in several countries across the world with another 60 in the process.
"ICMR study shows Covaxin neutralises against multiple variants of SARS-CoV-2 and effectively neutralises the double mutant strain as well," the ICMR tweeted.
ICMR-National Institute of Virology has successfully isolated and cultured multiple variants of concern of SARS-CoV-2 virus: B.1.1.7 (the UK variant), B.1.1.28 (Brazil variant ) and B.1.351 (South Africa variant).
ICMR-NIV has demonstrated the neutralisation potential of Covaxin against the UK variant and Brazil variant, the top health research body said.
ICMR-NIV recently has been successful in isolating and culturing the double mutant strain B.1.617 SARS-CoV-2 identified in certain regions of India and several other countries, the ICMR stated.
"Covaxin has been found to effectively neutralise the double mutant strain as well," it said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent Top Medical Body ICMR Warns Against Overcooking Dal, Saying It May Affect Nutritional Value Top Medical Body ICMR Advises People To Buy Whole Spices To Avoid Adulteration Over 300 Indian Students Return As Quota Row Sparks Violence In Bangladesh "Jindal Group Executive Showed Porn, Groped Me On Flight": Woman To NDTV Full Recovery From Global IT Outage Could Take Time: 10 Points CrowdStrike: All About The Cybersecurity Giant Behind Global IT Outage UP Government Forms Lucknow-SCR On The Lines Of Delhi-NCR The Situation At Delhi, Mumbai Airports Day After Global IT Outage Track Latest News Live on NDTV.com and get news updates from India and around the world.